DrugRisk Center Alerts that Judge Sets Deadline for Evidence in the Boehringer Ingelheim Pradaxa Bleeding Lawsuits

The Drug Risk Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
pradaxa lawsuit
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.

Dallas, TX (PRWEB) December 05, 2012

The DrugRisk Resource Center, a patient awareness group, is alerting patients taking Pradaxa that U.S. District Judge David Herndon, who presides over the growing litigation surrounding the blood thinner, recently ordered that manufacturer Boehringer Ingelheim will have until December 17th to produce evidence disputing claims that the drug can cause dangerous or fatal bleeding.*

Due to the growing number of Pradaxa lawsuits, cases have been moved to a special federal court in Illinois. The formal case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

In its latest report of November 14, 2012, the Judicial Panel on MultiDistrict Litigation indicated the number of Pradaxa internal bleeding cases has increased 50% since September 5th.**

Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.

Researchers disagree on the safety of Pradaxa. The Journal for the American Medical Association warned on September 3, 2012 that the FDA may have rushed its approval, overlooking key Pradaxa side effects like internal bleeding. In its latest study released November 4, 2012, however, the FDA stated that, for now, Pradaxa carries the same risk as other blood thinners.

On October 3, 2012, the Institute for Safe Medicine Practices’ QuarterWatch (PDF) estimated that prescription drug complaints to the FDA have risen 90% in the past 4 years, and two drugs, Pradaxa and Chantix, are responsible for 37% of that increase.

Although every type of blood thinner can lead to internal bleeding, the Journal of Neurosurgery reported doctors’ concerns on March 6, 2012 that, once Pradaxa causes internal bleeding, there is little they can do to stop it.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*http://www.ilsd.uscourts.gov/opinions/ilsd_live.3.12.md.2385.2208479.0.pdf#search=%22pradaxa%22
**http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets-By-District-November-2012.pdf


Contact